Citigroup
LEXX icon

Citigroup’s Lexaria Bioscience LEXX Stock Holding History

Citigroup’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33
Closed -$381 – 6025
2026
Q1 		$381 Buy
+33
New +$359 ﹤0.01% 5550
2025
Q4 		– Sell
-29
Closed -$409 – 6283
2025
Q3 		$409 Buy
+29
New +$421 ﹤0.01% 5724
2022
Q3 		– Sell
-82
Closed -$4K – 6106
2022
Q2 		$4K Buy
+82
New +$3.3K ﹤0.01% 5689

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup's LEXX Position: Q2 2026 in Review

Citigroup sold out of Lexaria Bioscience (LEXX) in Q2 2026, closing a stake of 33 shares — an estimated $381 sold.

Citigroup first reported a position in LEXX in Q2 2022 and held it in 3 quarters. The position peaked at $4K in Q2 2022. 29 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

  • Citigroup reported no remaining Lexaria Bioscience position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 33 Lexaria Bioscience shares in Q2 2026, an estimated $381.
  • Citigroup first reported a position in Lexaria Bioscience in Q2 2022 and held it in 3 quarters.
  • Citigroup's Lexaria Bioscience position peaked at $4K in Q2 2022.
  • 29 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.